Edition:
India

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

21.11USD
15 Feb 2019
Change (% chg)

$0.99 (+4.92%)
Prev Close
$20.12
Open
$20.12
Day's High
$21.14
Day's Low
$19.72
Volume
616,779
Avg. Vol
314,432
52-wk High
$33.39
52-wk Low
$13.90

Latest Key Developments (Source: Significant Developments)

Vanda Pharmaceuticals Inc - QTRLY Earnings Per Share $0.19
Thursday, 14 Feb 2019 

Vanda Pharmaceuticals Inc ::VANDA PHARMACEUTICALS REPORTS FOURTH QUARTER 2018 AND FULL YEAR 2018 FINANCIAL RESULTS.QTRLY EARNINGS PER SHARE $0.19.SEES YEAR-END 2019 CASH OF GREATER THAN $260 MILLION.TOTAL NET PRODUCT SALES FROM HETLIOZ AND FANAPT WERE $53.0 MILLION IN Q4 OF 2018, A 20% INCREASE.SEES COMBINED NET PRODUCT SALES FROM BOTH HETLIOZ AND FANAPT OF $215 TO $225 MILLION IN 2019.Q4 EARNINGS PER SHARE VIEW $0.01, REVENUE VIEW $51.6 MILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $232.5 MILLION -- REFINITIV IBES DATA.  Full Article

Vanda Announces Positive Pivotal Study Results For HETLIOZ (Tasimelteon) In Patients With Smith-Magenis Syndrome
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Vanda Pharmaceuticals Inc ::VANDA ANNOUNCES POSITIVE PIVOTAL STUDY RESULTS FOR HETLIOZ® (TASIMELTEON) IN PATIENTS WITH SMITH-MAGENIS SYNDROME.VANDA PHARMACEUTICALS INC - TASIMELTEON MET PRIMARY ENDPOINT OF IMPROVEMENT IN 50% WORST SLEEP QUALITY.VANDA PHARMACEUTICALS INC - TASIMELTEON DEMONSTRATED SIGNIFICANT IMPROVEMENT IN OVERALL SLEEP QUALITY (DDSQ) & OVERALL TOTAL NIGHTTIME SLEEP DURATION.VANDA PHARMACEUTICALS - INTENDS TO MEET WITH REGULATORY AUTHORITIES & SEEK MARKETING AUTHORIZATION FOR TREATMENT OF SMS PATIENTS WITH TASIMELTEON.VANDA PHARMACEUTICALS INC - FDA GRANTED ORPHAN DRUG DESIGNATION FOR TASIMELTEON FOR TREATMENT OF SMS.  Full Article

Vanda Receives FDA Letter Regarding Corporate Webpage
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Vanda Pharmaceuticals Inc ::VANDA RECEIVES FDA LETTER REGARDING CORPORATE WEBPAGE.INTENDS TO MEET WITH FDA TO BETTER UNDERSTAND REASONING OF LETTER.VANDA MODIFIED CONTENT OF WEBPAGE ON OCTOBER 23, 2018..  Full Article

Vanda Pharmaceuticals Quarterly Earnings Per Share $0.09
Thursday, 2 Aug 2018 

Aug 1 (Reuters) - Vanda Pharmaceuticals Inc ::VANDA PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.VANDA PHARMACEUTICALS INC SAYS REITERATES 2018 NET PRODUCT SALES GUIDANCE OF $180 MILLION TO $200 MILLION.VANDA PHARMACEUTICALS INC QUARTERLY TOTAL REVENUES $47.35 MILLION VERSUS $42.06 MILLION.VANDA PHARMACEUTICALS INC QUARTERLY EARNINGS PER SHARE $0.09.  Full Article

Vanda Pharmaceuticals Wins Appeal Case On Fanapt
Friday, 13 Apr 2018 

April 13 (Reuters) - Vanda Pharmaceuticals Inc ::VANDA WINS APPEAL CASE ON FANAPT®.U.S. FEDERAL COURT AFFIRMED U.S. COURT'S DECISION THAT WEST WARD PHARMACEUTICALS INFRINGED CO'S U.S. '610 PATENT FOR FANAPT.'610 PATENT IS SET TO EXPIRE NOVEMBER 2, 2027.  Full Article

Vanda receives negative opinion for marketing authorization from the European Medicines Agency
Saturday, 11 Nov 2017 

Nov 10 (Reuters) - Vanda Pharmaceuticals Inc ::Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia.Vanda Pharmaceuticals Inc - ‍CHMP re-examined its negative opinion and confirmed refusal of fanaptum MAA​.  Full Article

Vanda Pharmaceuticals posts qtrly ‍net loss of $0.10​/share
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Vanda Pharmaceuticals Inc :Qtrly ‍net loss per share $0.10​.  Full Article

Vanda Pharmaceuticals reached a pricing agreement with the German National Association of Statutory Health Insurance Funds
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Vanda Pharmaceuticals Inc :Vanda Pharmaceuticals - On Oct 17, co reached a pricing agreement with the German National Association of Statutory Health Insurance Funds.Vanda Pharmaceuticals - Pricing agreement for treatment of totally blind individuals with sleep-wake disorder with Hetlioz after an arbitration board decision.Vanda Pharmaceuticals - ‍Ex-factory price of Hetlioz in Germany expected to be about eur 69,000/year, effective date of Aug 1, 2017​ - SEC Filing.  Full Article